Brigatinib/Brigatinib vs. Lorlatinib: Comparison of Two ALK Inhibitors

Brigatinib and Lorlatinib are important drugs for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations, especially ALK-positive tumors. Although they are all tyrosine kinase inhibitors, there are significant differences in treatment strategies, indications, and drug properties.

Brigatinib, usually considered as the first choice after crizotinib treatment failure, is particularly effective in inhibitingALK mutations and can even combat some mutations that are resistant to first-line treatment. Its efficacy has been clearly demonstrated in clinical trials. In the pivotal Phase 2 clinical trial known as ALTA, patients with ALK-positive metastatic NSCLC who were resistant or intolerant to crizotinib experienced an objective response rate (ORR) of 45-56% after receiving brigatinib, depending on the dose administered. Furthermore, brigatinib showed potential in controlling disease progression, with median progression-free survival (PFS) ranging from 13.8 to 16.7 months. It is worth mentioning that brigatinib is also effective against central nervous system (CNS) metastasis, a common problem in ALK-positive NSCLC. In the ALTA trial, the intracranial response rate was quite encouraging, with many patients experiencing a reduction in central nervous system lesions.

Larlatinib is another high-profileALK inhibitor, which was originally designed to inhibit the most common ALK mutations, even those that confer resistance to other ALK inhibitors. Lorlatinib has shown particular efficacy in patients who have been previously treated with one or more ALK inhibitors. In a phase 2 clinical trial, lorlatinib achieved an ORR of 47% in patients who had received at least one ALK inhibitor. The median PFS was also considerable, with patients experiencing a median duration of 7.0 months before disease progression. Similar to brigatinib, lorlatinib also performs well in controlling central nervous system metastases in patients with ALK-positive NSCLC. Clinical studies have shown that lorlatinib can bring about significant intracranial responses, thus demonstrating its effectiveness in the treatment and control of brain metastases. This property is particularly important in patients with advanced disease, since central nervous system involvement is often associated with poor prognosis.

In general, both brigatinib and lorlatinib have shown significant efficacy in the treatment of ALK-positive NSCLC. Which drug is chosen depends on a variety of factors, including the patient's specific condition, previous treatment history, and the drug's side effects. Therefore, when formulating a treatment plan, doctors will make individualized choices based on the patient's specific conditions.